GastroparesisPhase 3NCT03383146
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
A Phase 3 study testing Relamorelin in people with Gastroparesis and Diabetes Mellitus, run by Allergan at 349 sites in 27 countries.
Trial summary
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastroparesis, Diabetes Mellitus
- What is being tested?
- Relamorelin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 450 participants
- Where
- 349 sitesin 27 countries
- Study dates
- 1 Feb 2018to 5 Nov 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Two different groups of participants may enter into the study:
- Rollover Participants
- Participants who were not randomization-eligible at the end of the Run-in Period of lead-in studies RLM-MD-01 (NCT03285308) or RLM-MD-02 (NCT03426345) are eligible to be randomized in the study if all of the following criteria apply:
- •In the lead-in studies, participants must have met all screening visit and Run-in Period criteria for randomization into the Treatment Period (including compliance with dosing, entry of diary data into the Diabetic Gastroparesis Symptom Severity Diary (DGSSD)) except that:
- They had zero vomiting episodes and an average daily Diabetic Gastroparesis Symptom Severity Score (DGSSS) of ≥12 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device; OR
- They had vomiting episodes and an average daily DGSSS of ≥12 but <16 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device
Show all 12Show fewer
- De Novo Participants
- Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) of at least 5 years' duration, with controlled and stable blood glucose levels and hemoglobin A1c (HBA1c) ≤11%
- DG defined as at least a 3-month history prior to Screening of symptoms (one of which must be nausea) on an ongoing basis that are suggestive of gastroparesis (GP) (e.g., nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety)
- Compliance with the entry of data into the hand-held electronic device during the Run-in Period
- Compliance with administration of subcutaneous (SC) twice daily injections during the Run-in Period
- The average of the daily DGSSS from the 2-week, Run-in Period must be ≥12
Who cannot join
- Both Rollover and De Novo Participants
- •Participants with a known allergy or hypersensitivity to the study treatments and their excipients (i.e., mannitol or phenol)
- Rollover Participants
- •Participants will be excluded from this study if any of the lead-in study exclusion criteria apply at the Screening Visit and at the end of the Run-in Period for randomization into the Treatment Period of studies RLM-MD-01 and RLM-MD-02, except as specified in the inclusion criteria
- De Novo Participants
- History of anorexia nervosa, binge-eating, bulimia, or other eating disorder within 5 years of the Screening Visit
Show all 18Show fewer
- History of intestinal malabsorption or pancreatic exocrine insufficiency
- History of belching disorders, other nausea and vomiting disorders
- Gastric or duodenal ulcer within 3 months of Screening
- History of malignancy in the 3 years prior to Screening, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
- Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression
- Use of metoclopramide, domperidone, prucalopride, macrolide antibiotics (e.g., erythromycin, clarithromycin, azithromycin), or other drugs considered to be GI promotility agents for at least 10 days prior to the start of the Run-in Period
- Currently taking opiates, or expecting to use opiates during the course of the clinical study
- Treatment with glucagon-like peptide-1 (GLP-1) agonist for at least 6 weeks prior to the start of the Run-in Period
- History of pyloric injection of botulinum toxin within 6 months of screening
- History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure (a history of diagnostic endoscopy is not exclusionary)
- Randomization in any previous study in which relamorelin was a treatment
- Allergic to, or intolerant of egg, wheat, milk, or algae, as these are components of the gastric emptying breath test (GEBT) study meal
Trial locations and contacts
349 sites in 27 countries.
349 sites in 27 countries
United States183 sites
Synexus Clinical Research US, Inc.
Akron, Ohio, 44311
Lovelace Scientific Resources, Inc.
Albuquerque, New Mexico, 87108
Synexus Clinical Research US, Inc.
Anderson, South Carolina, 29621
Synexus Clinical Research US, Inc
Anderson, South Carolina, 29621
Pinnacle Research Group
Anniston, Alabama, 36207
Texas Clinical Research Institute, LLC
Arlington, Texas, 76012
Asheville Gastroenterology Associates
Asheville, North Carolina, 28801
North Alabama Research Center, LLC
Athens, Alabama, 35611
Atlanta Diabetes Associates
Atlanta, Georgia, 30318
DiscoveResearch, Inc.
Beaumont, Texas, 77701
Dayton Gastroenterology,Inc.
Beavercreek, Ohio, 45440
Simon Williamson Clinic
Birmingham, Alabama, 35211
River Birch Research Alliance, LLC
Blue Ridge, Georgia, 30513
WK Physicians Network
Bossier City, Louisiana, 71111
Garden State Endocrinology LLC
Brick, New Jersey, 08723
Gastroenterology Associates of Fairfield County, P.C.
Bridgeport, Connecticut, 06606
Synexus Clinical Research US, Inc.
Bridgeton, New Jersey, 08302
Gwinnett Research Institute, LLC
Buford, Georgia, 30519
Hope Clinical Research
Canoga Park, California, 91303
Diabetes & Endocrinology Associates of Stark County, Inc.
Canton, Ohio, 44718
Summit Clinical Research, LLC.
Carnesville, Georgia, 30521
ClinRx Research, LLC
Carrollton, Texas, 75007
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7080
Clinical Trials of South Carolina
Charleston, South Carolina, 29406
Carolinas Healthcare-Charlotte
Charlotte, North Carolina, 28204
Clinsearch
Chattanooga, Tennessee, 37421
Clinical Research Institute of Michigan
Chesterfield, Michigan, 48047
Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
GW Research Inc
Chula Vista, California, 91910
Synexus Clinical Research US - Cincinnati
Cincinnati, Ohio, 45236
Synexus Clinical Research US, Inc
Cincinnati, Ohio, 45249
Innovative Research of West FL, Inc.
Clearwater, Florida, 33756
Clinical Research of West Florida
Clearwater, Florida, 33765
Carolina Medical Research
Clinton, South Carolina, 29325
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907
Synexus
Colorado Springs, Colorado, 80909
Gastro Center of Maryland
Columbia, Maryland, 21045
Endocrinology Research Associates, Inc.
Columbus, Ohio, 43201
The Ohio State University, Wexner Medical Center
Columbus, Ohio, 43203
Aventiv Research, Inc.
Columbus, Ohio, 43213
Hometown Urgent Care and Research
Columbus, Ohio, 43214
Carolina Digestive Health Associates, PA
Concord, North Carolina, 28025
MNGI Digestive Health
Coon Rapids, Minnesota, 55446
ALL Medical Research, LLC
Cooper City, Florida, 33024
Kindred Medical Institute for Clinical Trials, LLC
Corona, California, 92879
Aurora Care Clinic, LLC
Costa Mesa, California, 92627
Avant Research Associates LLC
Crowley, Louisiana, 70526
Top Medical Research
Cutler Bay, Florida, 33189
CIC America Clinical Inquest Center Ltd.
Dayton, Ohio, 45409
Hometown Urgent Care and Research
Dayton, Ohio, 45424
Vida Clinical Studies
Dearborn, Michigan, 48124
iResearch Atlanta LLC
Decatur, Georgia, 30030
Digestive Health Specialist of the South East
Dothan, Alabama, 36305
AGA Clinical Research Associates, LLC
Egg Harbor, New Jersey, 08234
TriWest Research Associates
El Cajon, California, 92020
Diagnamics Inc.
Encinitas, California, 92024
St. Elizabeth Healthcare â€" Clinical Research Institute
Erlanger, Kentucky, 41018
North Shore University Health System
Evanston, Illinois, 60201
MediSphere Medical Research Center, LLC
Evansville, Indiana, 47714
Synexus Clinical Research US, Inc.
Evansville, Indiana, 47714
Verity Research Inc.
Fairfax, Virginia, 22031
Cumberland Research Associates, LLC
Fayetteville, North Carolina, 28304
Aa Mrc, Llc
Flint, Michigan, 48504
G & L Research, LLC
Foley, Alabama, 36535
Premier Clinical Research d.b.a. STAT Research
Franklin, Ohio, 45005
Frederick Gastroenterology Associates, PA an Elligo Health Research Site
Frederick, Maryland, 21701
VVCRD Research
Garden Grove, California, 92845
Gastroenterology Centers of the Midsouth
Germantown, Tennessee, 38138
Woodholme Gastroenterology Associates, P.A.
Glen Burnie, Maryland, 21061
Long Island Gastrointestinal Research Group LLP
Great Neck, New York, 11023
Triad Clinical Trials
Greensboro, North Carolina, 27410
Gastroenterology Associates, PA
Greenville, South Carolina, 29615
Synexus Clinical Research
Greer, South Carolina, 29650
Meritus Center for Clinical Research
Hagerstown, Maryland, 21742
Medical Research Center of Connecticut, LLC
Hamden, Connecticut, 06518
National Clinical, LLC
Hamtramck, Michigan, 48212
Palmetto Research, LLC
Hialeah, Florida, 33016
Vida Clinical Trials
Homestead, Florida, 33030
Cronola LLC
Houma, Louisiana, 70360
Baylor College of Medicine Medical Center
Houston, Texas, 77030
Biopharma Informatic Inc., Research Center
Houston, Texas, 77043
Houston Endoscopy and Research Center, Inc.
Houston, Texas, 77079
Rodriguez Clinical Trials
Houston, Texas, 77083
Amir Hassan, MD, PA
Houston, Texas, 77089
Avant Research Associates
Huntsville, Alabama, 35801
Rocky Mountain Diabetes and Osteoporosis Center, PA
Idaho Falls, Idaho, 83404-7596
Nature Coast Clinical Research
Inverness, Florida, 34452
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
American Research, LLC
Jeffersonville, Indiana, 47130
United Health Services Hospitals, Inc.
Johnson City, New York, 13790
East Tennessee Research Institute
Johnson City, Tennessee, 37604
University of Kansas Medical Center
Kansas City, Kansas, 66160
Sante Clinical Research
Kerrville, Texas, 78028
Vidant Multispeciality Clinic - Kinston
Kinston, North Carolina, 28501
University of California San Diego
La Jolla, California, 92037
Clinical Trials of SWLA, LLC
Lake Charles, Louisiana, 70601
Om Research LLC
Lancaster, California, 93534
Excel Clinical Research
Las Vegas, Nevada, 89109
Clinical Research of South Nevada - CROSN
Las Vegas, Nevada, 89121
Advanced Biomedical Research of America
Las Vegas, Nevada, 89123
Digestive Disease Specialists
Las Vegas, Nevada, 89128
Palm Research Center
Las Vegas, Nevada, 89135
Synexus Clinical Research US, Inc.
Layton, Utah, 84041
Family Medical Associates, Research Department
Levittown, Pennsylvania, 19056
Preferred Research Partners, Inc.
Little Rock, Arkansas, 72211
Applied Research Center of Arkansas
Little Rock, Arkansas, 72212
Torrance Clinical Research Institute, Inc.
Lomita, California, 90717
Angel City Research Inc.
Los Angeles, California, 90057
University of Louisville
Louisville, Kentucky, 40202
Blue Ridge Medical Research
Lynchburg, Virginia, 24502
Manassas Clinical Research Centre
Manassas, Virginia, 20110
Tandem Clinical Research
Marrero, Louisiana, 70072
APF Research LLC
Miami, Florida, 33134
AMPM Research Clinic
Miami, Florida, 33169
Advanced Medical Research Institute
Miami, Florida, 33174
Florida Research Center, Inc.
Miami, Florida, 33174
American Research Institute, Inc
Miami, Florida, 33175
Savin Medical Group LLC
Miami Lakes, Florida, 33014
Montana Medical Research
Missoula, Montana, 59808
Alabama Medical Group, PC
Mobile, Alabama, 36608
Diabetes and Endocrinology Consultants, PC
Morehead City, North Carolina, 28557
West Virginia University
Morgantown, West Virginia, 26506
Synexus Clinical Research US, Inc.
Murray, Utah, 84123
Gastroenterology Group of Naples
Naples, Florida, 34102
Quality Medical Research
Nashville, Tennessee, 37211
Arkansas Gastroenterology
North Little Rock, Arkansas, 72117
Southwest Gastroenterology
Oak Lawn, Illinois, 60453
Sensible Healthcare
Ocoee, Florida, 34761
Advanced Research Institute, Inc.
Ogden, Utah, 84405
Centennial Health-Synexus
Oklahoma City, Oklahoma, 73111
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma, 73112
Memorial Clinical Research
Oklahoma City, Oklahoma, 73120
Diabetes and Endocrine Associates, P.C.
Omaha, Nebraska, 68114
Heartland Clinical Research, Inc
Omaha, Nebraska, 68134
Stanford Hospital
Palo Alto, California, 94304
Phoenix Clinical LLC.
Phoenix, Arizona, 85014
Synexus
Pinellas Park, Florida, 33781
Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania, 15212
Preferred Primary Care Physicians, Inc.
Pittsburgh, Pennsylvania, 15236
Northwest Gastroenterology Clinic, LLC
Portland, Oregon, 97210
Health Science Research Center
Pratt, Kansas, 67124
Health Concepts
Rapid City, South Dakota, 57702
Synexus Clinical Research US, Inc.
Richfield, Minnesota, 55423
VA Medical Center McGuire VAMC
Richmond, Virginia, 23249
Infinite Clinical Trials
Riverdale, Georgia, 30274
Meridian Clinical Research, LLC
Rockville, Maryland, 20854
PMG Research Salisbury
Salisbury, North Carolina, 28144
Pinnacle Clinical Research
San Antonio, Texas, 78215
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229
Sagact Pllc.
San Antonio, Texas, 78229
Synexus Clinical Research US, Inc.
San Antonio, Texas, 78229
Optimal Research California
San Diego, California, 92108
Medical Associates Research Group, Inc
San Diego, California, 92123
Syrentis Clinical Research
Santa Ana, California, 92705
Guthrie Clinical Research
Sayre, Pennsylvania, 18840
Frontier Clinical Research, LLC
Scottdale, Pennsylvania, 15683
Unity Health - Searcy Medical Center
Searcy, Arkansas, 72143
WestGlen Gastrointestinal Consultants
Shawnee Mission, Kansas, 66217
Frontier Clinical Research, LLC
Smithfield, Pennsylvania, 15478
Synexus Clinical Research US, Inc
St Louis, Missouri, 63141
Clinical Research Consultants of Atlanta
Suwanee, Georgia, 30024
Washington Gastroenterology PLLC
Tacoma, Washington, 98405
CHEAR Center LLC
The Bronx, New York, 10455
Cotton-O'Neil Clinical Research Center - Digestive Health
Topeka, Kansas, 66606
Kansas Medical Clinic
Topeka, Kansas, 66606
Del Sol Research Management, LLC
Tucson, Arizona, 85710
Del Sol Research Management, LLC
Tucson, Arizona, 85712
Synexus Clinical Research US, Inc.
Tucson, Arizona, 85741
Options Health Research, LLC
Tulsa, Oklahoma, 74104
Preferred Primary Care Physicians
Uniontown, Pennsylvania, 15401
Upland Clinical Research
Upland, California, 91786
Synexus Clinical Research US, Inc.
Vista, California, 92083
Family Practice Center of Wadsworth, Inc.
Wadsworth, Ohio, 44281
Advanced Clinical Research
West Jordan, Utah, 84088
Clinical Trials of America, Inc.
West Monroe, Louisiana, 71291
New Hope Research Development
Whittier, California, 90603
Professional Research Network of Kansas, LLC
Wichita, Kansas, 67205
Via Christi Clinic, PA
Wichita, Kansas, 67208
PMG Research of Wilmington, LLC
Wilmington, North Carolina, 28401
Trial Management Associates, LLC
Wilmington, North Carolina, 28403
PMG Research of Winston-Salem, LLC
Winston-Salem, North Carolina, 27103
The Center for Clinical Research
Winston-Salem, North Carolina, 27103
Gastroenterology Associates of Western Michigan, West Michigan Clinical Research Center
Wyoming, Michigan, 49519
India22 sites
Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology
Ahmedabad, Gujarat, 380007
Zydus Hospital
Ahmedabad, Gujarat, 380054
Lifecare Clinic and Research Centre - Internal Med/Diabetology
Bangalore, Karnataka, 560092
Diacon Hospital and research Center - Diabetology
Bengaluru, Karnataka, 359-360
Victoria Hospital Bangalore Medical College and Research Institute
Bengaluru, Karnataka, 560002
Rajalakshmi Hospital
Bengaluru, Karnataka, 560097
M.V. Hospital for Diabetes & Diabetes Research Centre
Chennai, Tamil Nadu, 600013
Kovai Diabetes Speciality Centre
Coimbatore, Tamil Nadu, 641009
Sir Ganga Ram Hospital (SGRH)
Delhi, 110060
Kumudini Devi Diabetes Research Center; Ramdevrao Hospital
Hyderabad, Andhra Pradesh, 500072
S R Kalla (SRK) Memorial Gastro & General Hospital
Jaipur, Rajasthan, 302001
Marudhar Hospital
Jaipur, Rajasthan, 302012
Eternal Hospital - Diabetology
Jaipur, Rajasthan, 302017
SMS Hospital
Jaipur, Rajasthan, 302017
M V Hospital & Research Centre
Lucknow, Uttar Pradesh, 226003
Arthur Asirvatham Hospital
Madurai, Tamil Nadu, 625020
Vinaya Hospital & Research Centre
Mangalore, 575003
Bhatia Hospital
Mumbai, Maharashtra, 400007
B. J. Government Medical College and Sassoon General Hospitals
Pune, Maharashtra, 411001
Universal Hospital
Pune, Maharashtra, 411011
Noble Hospital
Pune, Maharashtra, 411013
King George Hospital
Visakhapatnam, Andhra Pradesh, 530002
Ukraine16 sites
Chernivtsi Regional Clinical Hospital
Chernivtsi, 58001
Regional Municipal noncommercial Enterprise "Chernivtsi Regional Endocrinology Center", Polyclinic department, Higher State Educational Establishment of Ukraine "Bukovinian State Medical University", Department of Clinical Immunology, Allergology and Endo
Chernivtsi, 58022
State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine
Dnipro, Dnipropetrovsk Oblast, 49027
Ivano-Frankivsk National Medical University
Ivano-Frankivsk, 76008
Ivano-Frankivsk Central City Clinical Hospital
Ivano-Frankivsk, 76018
Municipal nonprofit entity of Kharkiv municipal council
Kharkiv, 61037
Clinical Endocrinology of SI "V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"
Kharkiv, 61070
Communal Institution Kherson City Clinical Hospital
Kherson, 73000
Kyiv Railway Clinical Hospital No-2 of Branch of Healthcare Center of the PJSC Ukrainian Railway , Endocrynology Department
Kyiv, 3049
Polyclinic of medical services and rehabilitation department of State Joint-Stock Holding Company Artem, day-patient unit
Kyiv, 4050
Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University
Odesa, 65010
Poltava Regional Clinical Hospital
Poltava, 36011
Private Small-Scale Enterprise Medical Centre Pulse
Vinnytsia, 21001
Vinnytsia Regional Clinical highly specialized Endocrinology Centre
Vinnytsia, 21010
Municipal Institution, City Hospital #7, polyclinic department, c. Zaporizhzhia
Zaporizhzhya, Zaporizhzhia Oblast, 69600
Municipal Institution 6th City Clinical Hospital, Dept of Gastroenterology
Zaporizhzhya, 69035
Mexico13 sites
Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV
Aguascalientes, 20230
Hospital Cardiologica Aguascalientes
Aguascalientes, 20230
Dioderm Instituto de Investigacion
Durango, 34060
CIADEN (Centro de Investigación y Atención de Diabetes, Endocrinología y Nutrición)
Durango, 34270
Unidad de Investigacion Clinica Cardiometabolica de Occidente
Guadalajara, Jalisco, 44150
Consultorio particular
Guadalajara, Jalisco, 44210
Unidad de Investigación Clínica en Medicina S.C/
Guadalajara, Jalisco, 44670
Centro de Desarrollo Biomédico S.C.P
Mérida, Yucatán, 97070
Clinicos Asociados BOCM SC
Mexico City, Mexico City, 03300
Mentrials Sa de Cv
Mexico City, Mexico City, 06700
Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology
Mexico City, Mexico City, 11650
Centro de Atención e Investigación en Factores de Riesgo Car
Mexico City, Mexico City, 14000
Sociedad de Metabolismo y Corazon S.C.
Veracruz, 91900
Colombia11 sites
Centro Cardiovascular y de Diabetes
Barranquilla, Atlántico, 080020
Fundación del Caribe para la InvestigacionBiomédica-Fundación BIOS
Barranquilla, Atlántico, 080020
Medplus Centro de Recuperacion Integral S.A.S.
Bogotá, Bogota D.C., 110221
Endocare Ltda.
Bogotá, Bogota D.C., 111111
Asociación Colombiana de Diabetes
Bogotá, Cundinamarca, 111311
IPS Centro Medico Julian Coronel S.A
Cali, Valle del Cauca Department, 760035
Centro Medico Imbanaco de Cali S.A.
Cali, Valle del Cauca Department, 760042
Rodrigo Botero S.A.S.
Medellín, Antioquia, 050030
Centro Cardiovascular Colombiano Clínica Santa María
Medellín, Antioquia, 050034
Centro de Investigaciones Clínicas IPS CARDIOMET Pereira
Pereira, Risaralda Department, 660003
Healthy Medical Center
Zipaquirá, Cundinamarca, 250252
United Kingdom11 sites
MAC Research
Barnsley, S75 3DL
MAC Clinical Research, Kaman Court
Blackpool, FY2 0JH
MAC Research, Exchange House
Cannock, Staffordshire, WS11 0BH
Mid Essex Hospital Services NHS Trust Broomfield Hospital
Chelmsford, CM1 7ET
MAC Clinical Research, Monarch House
Leeds, West Yorkshire, LS10 1DU
MAC Clinical Research
Liverpool, Merseyside, L34 1BH
MAC Clinical Research Manchester
Manchester, Greater Manchester, M13 9NQ
MAC Clinical Research, GAC House
Manchester, M13 9NQ
Biomedical Research Centre
Nottingham, East Midland, NG7 2UH
Royal Oldham Hospital
Oldham, Lancashire, OL1 2JH
University Hospitals of North Midlands
Stoke-on-Trent, Staffordshire, ST6 8DG
Argentina10 sites
Consultorios Asociados de Endocrinologia e Investigación Cl
Buenos Aires, Buenos Aires, C1425AGC
CIPREC
Buenos Aires, Ciudad Autonoma deBuenos Aires, 1119
Hospital Sirio Libanes
CABA, Buenos Aires, C1419AHN
Instituto Privado de Investigaciones Clinicas de Cordoba
Córdoba, X5000AAW
CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegian
Córdoba, X5000BNB
Centro Universitario de Investigacion en Farmacologia Clinic
Corrientes, W3410AVV
Centro de Investigaciones Medicas Mar del Plata SRL
Mar del Plata, Buenos Aires, B7600FYK
Instituto de Investigaciones Clinicas de Rosario
Rosario, Santa Fe Province, S2000BIE
Instituto Medico Catamarca-I.ME.C
Rosario, Santa Fe Province, S200CFK
Clinica Mayo de Urgencias Medicas Cruz Blanca SRL
San Miguel de Tucumán, Tucumán Province, 4000
Brazil10 sites
Hospital Universitário João de Barros Barreto - UFPA
Belém, Pará, 66073-005
Centro de Pesquisa Clinica do Brasil
Brasília, Federal District, 71625175
Scentryphar Pesquisa Clínica Ltda
Campinas, São Paulo, 13020-431
Instituto de Pesquisa Clinica em Campinas
Campinas, São Paulo, 13060-080
Hospital Universitário Walter Cantídio
Fortaleza, Ceará, 60430-270
Instituto de Estudos e Pesquisas Clinicas do Ceara IEP/CE - Oncology
Fortaleza, 60160-230
Instituto Catarinense de Endocrinologia e Diabetes (ICED)
Joinville, Santa Catarina, 89201-260
Núcleo de Pesquisa Clínica do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, 90430-001
IPEC-Instituto de Pesquisa Clinica
São Paulo, 01223-001
CPQuali Pesquisa Clinica Ltda
São Paulo, 01228-000
Canada8 sites
South Shore Medical Arts
Bridgewater, Nova Scotia, B4V 3N2
University of Calgary
Calgary, Alberta, T2N 2T9
Recherche GCP Research
Montreal, Quebec, H1M 1B1
The Ottawa Hospital
Ottawa, Ontario, K1H 7W9
Central Alberta Research Centre
Red Deer, Alberta, T4N 6V7
Patient research centre
St. John's, Newfoundland and Labrador, A1B 3V6
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9
Toronto Digestive Disease Associates, Inc.
Vaughan, Ontario, L4L 4Y7
Philippines7 sites
Perpetual Succor Hospital
Cebu City, 6000
West Visayas State University Medical Center
Iloilo City, IloIlo, 5000
Ospital ng Makati
Makati City, NCR, 1218
Manila Doctors Hospital, Ermita
Manila, Metropolitan Manila, 1000
San Juan De Dios Educational Foundation, Inc.
Pasay, Metropolitan Manila, 1300
St. Luke's Medical Center
Quezon City, 1100
Cardinal Santos Medical Center
San Juan City, National Capital Region, 1502
Germany6 sites
Studienzentrum Schwittay
Böhlen, Saxony, 4564
Klinische Forschung Dresden GmbH
Dresden, Saxony, 1309
Clinical Research Hamburg
Hamburg, 22143
Israelitisches Krankenhaus
Hamburg, 22297
KRH Klinikum Siloah
Hanover, 30459
Klinische Forschung Karlsruhe GmbH
Karlsruhe, Baden-Wurttemberg, 76199
Hungary5 sites
Strázsahegy Gyógyszertár Medicina
Budapest, H1171
Markhot Ferenc Oktatokorhaz es Rendelointezet
Eger, Heves County, H-3300
Szegedi TudomanyegyetemSzent-Gyorgyi Albert Klinikai Kozpont és Altalanos Orvostudomanyi Kar Belgyogyaszati Klinika
Szeged, H-6720
Hetenyi Geza Hospital
Szolnok, Jász-Nagykun-Szolnok, H-5004
Zala Megyei Szent Rafael Korhaz
Zalaegerszeg, Zala County, H-8900
South Africa5 sites
FARMOVS
Bloemfontein, Free State, 9301
Wits Clinical Research
Johannesburg, Gauteng, 2193
Synexus Stanza Clinical Research Centre
Pretoria, Gauteng, 0122
Watermeyer Clinical Research Site
Pretoria, Val de Grace, 0184
Synexus Helderberg Clinical Research Centre
Somerset West, 7130
Austria4 sites
VIVIT Institute, am LKH Feldkirch
Feldkirch, Vorarlberg, 6807
Ordination
Osterreicher, Styria, 8511
Privatklinik wehlre-Diakonissen
Salzburg, 5020
Oö. Gesundheits- und Spitals-AG/LKH Steyr
Steyr, 4400
Bulgaria4 sites
MHAT Yuliya Vrevska Byala
Byala, Ruse, 7100
UMHAT - Kaspela- EOOD
Plovdiv, 4002
Medical Center Asklepion - Humane Medicine Research EOOD
Sofia, 1303
Alexandrovska University Hospital
Sofia, 1431
Latvia4 sites
Polana-D
Daugavpils, LV5401
Kraslava Hospital
Krāslava, Kraslavas Nov., 5601
Pauls Stradins Clinical University Hospital, Endokrinologijas nodala
Riga, 1002
Digestive Diseases Centre GASTRO
Riga, 1006
Malaysia4 sites
Hospital Sultanah Bahiyah
Alor Star, Kedah, 5460
Clinical Investigation Centre
Kuala Lumpur, 59100
Clinical Trial Unit, School of Medical Sciences, Health Campus, Hospital Universiti Sains Malaysia
Kubang Kerian, 16150
Hospital Taiping
Taiping, 34000
Russia4 sites
Scientific Institute of Clinical and Experimental Lymphology
Novosibirsk, 630117
Rostov on Don
Rostov-on-Don, 344019
GUZ Saratov City Clinical Hospital 9
Saratov, Saratov Oblast, 410030
Saint-Petersburg City Pokrovskaya Hospital
St-Petersburg, Leningradskaya Oblast', 199106
Australia3 sites
Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated
Adelaide, South Australia, 5000
Nepean Hospital
Kingswood, New South Wales, 2747
Royal Melbourne Hospital
Parkville, Victoria, 3050
Belgium3 sites
AZ Sint Lucas Brugge
Bruges, West-Vlaanderen, 8310
Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,
Edegem, Antwerp, 2650
UZ Brussel
Jette, Brussels Capital, 1090
Poland3 sites
Centrum Medyczne Lukamed
Chojnice, 89-600
Specjalistyczny Gabinet Neurologiczny Marta Banach
Krakow, Lesser Poland Voivodeship, 30-539
CenterMed Krakow Ltd
Krakow, Malopolska, 31-530
Singapore3 sites
National University Hospital
Singapore, 119228
Changi General Hospital
Singapore, 529889
Singapore General Hospital
Singapore, S169856
South Korea3 sites
Chonbuk National University Hospital
Jeonju, Jeollabuk-do, 561-712
Sanggye Paik Hospital, Inje University College of Medicine
Seoul, Nowon-gu, 1757
Asan Medical Center
Seoul, 05505
Thailand3 sites
Phramongkutklao Hospital
Bangkok, 10400
Faculty of Medicine, Siriraj Hospital, Mahidol University
Bangkok, 10700
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, 50200
Denmark2 sites
Steno Diabetes Center Copenhagen
Hellerup, Copenhagen, 2900
Gastroenheden, Hvidovre hospital
Hvidovre, København, 2605
About this study
Official title: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
- Conditions
- Gastroparesis, Diabetes Mellitus
- Being tested
- Placebo, Relamorelin
- Keywords
- diabetic gastroparesis, vomiting
- Medical subject headings
- Gastroparesis, Diabetes Mellitus, Vomiting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Placebo injected subcutaneously twice daily.
RelamorelinDrug
Relamorelin 10 μg injected subcutaneously twice daily.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in. Receives: Drug: Placebo |
| Relamorelin 10 μg | Experimental | Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in. Receives: Drug: Relamorelin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Measured: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study
Change From Baseline to Week 52 in the Weekly Average DGSSS
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Measured: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 52 of this study
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
Measured: First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks)
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Measured: Up to 52 weeks
Number of Participants With Clinically Meaningful Trends for Vital Signs
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
Measured: Up to 52 weeks
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
Measured: Up to 52 weeks
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)
Measured: Up to 52 weeks
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
Measured: Baseline (Day 1), Day 84, Day 364, and End of Treatment (Up to Day 364)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2017
- Study start1 Feb 2018
- Primary completion5 Nov 2020
- Study completion5 Nov 2020
Why it stopped: The Relamorelin program is being terminated solely based on a business decision.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for GastroparesisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 450 participants (actual)
Sponsor and investigators
- Lead sponsor
- Allergan
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Harvy Schneier, Study director, Allergan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03383146
- Sponsor's protocol ID
- RLM-MD-04
- Other IDs
- 2017-002144-33, 2017
- Status last verified
- Nov 2021
- First submitted
- 19 Dec 2017
- Last updated
- 23 Nov 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
- ClinicalTrials.gov ID
- NCT03383146
- Acronym / sponsor ID
- RLM-MD-04
- Conditions
- Gastroparesis, Diabetes Mellitus
- Keywords
- diabetic gastroparesis, vomiting
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The Relamorelin program is being terminated solely based on a business decision.
- Enrolment
- 450 participants (actual)
- Lead sponsor
- AllerganIndustry (pharma, biotech, devices)
- Study start
- 1 Feb 2018 (actual)
- Primary completion
- 5 Nov 2020 (actual)
- Study completion
- 5 Nov 2020 (actual)
- First posted
- 26 Dec 2017 (actual)
- Results
- Posted 23 Nov 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboPlacebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in. |
| Relamorelin 10 μg | Experimental | Drug: RelamorelinRelamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Rollover Participants
- Participants who were not randomization-eligible at the end of the Run-in Period of lead-in studies RLM-MD-01 (NCT03285308) or RLM-MD-02 (NCT03426345) are eligible to be randomized in the study if all of the following criteria apply:
- •In the lead-in studies, participants must have met all screening visit and Run-in Period criteria for randomization into the Treatment Period (including compliance with dosing, entry of diary data into the Diabetic Gastroparesis Symptom Severity Diary (DGSSD)) except that:
- De Novo Participants
Key exclusion criteria (18 listed)
- Both Rollover and De Novo Participants
- •Participants with a known allergy or hypersensitivity to the study treatments and their excipients (i.e., mannitol or phenol)
- Rollover Participants
- •Participants will be excluded from this study if any of the lead-in study exclusion criteria apply at the Screening Visit and at the end of the Run-in Period for randomization into the Treatment Period of studies RLM-MD-01 and RLM-MD-02, except as specified in the inclusion criteria
- De Novo Participants
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboPlacebo injected subcutaneously twice daily. | Drug | Placebo |
| RelamorelinRelamorelin 10 μg injected subcutaneously twice daily. | Drug | Relamorelin 10 μg |
Primary outcome
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Change From Baseline to Week 52 in the Weekly Average DGSSS
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 52 of this study
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
Time frame: First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Time frame: Up to 52 weeks
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Number of Participants With Clinically Meaningful Trends for Vital Signs
Time frame: Up to 52 weeks
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
Time frame: Up to 52 weeks
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)
Time frame: Up to 52 weeks
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
Time frame: Baseline (Day 1), Day 84, Day 364, and End of Treatment (Up to Day 364)
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Nov 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Gastroparesis
Recruiting
Gastric Focused Ultrasound Stimulation
Gastroparesis, Delayed Gastric Emptying
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Enrolling by invitationObservational study
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
Motility Disorder, Gastroparesis
Not yet recruiting
Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
Gastric Cancer, Gastric Outlet Obstruction
Recruiting
To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.
Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Harvy Schneier study director
Allergan
349 sites in 27 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Relamorelin in people with Gastroparesis and Diabetes Mellitus, run by Allergan at 349 sites in 27 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 349 sites in United States, India, Ukraine, Mexico, Colombia and 22 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) (time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Nov 2021.